Evidence map›Paper›PMID 41126608›Full record

ReviewTherapeutic advances in respiratory disease

Prolonged survival of thoracic SMARCA4-deficient undifferentiated tumor with immune-related cystitis: a case report and literature review.

Xiang Li, Minshu Ao, Sen Tian, Yilin Chen, Hui Chen, Na Ta, Xiang Ni, Jingyu Zhang, Haidong Huang, Yao Fang and 6 more

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiang LiDepartment of Respiratory and Critical Care Medicine, General Hospital of Central Theater Command of the Chinese People's Liberation Army, Wuhan, China.ORCID 0009-0000-6182-161X
Minshu AoDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Sen TianDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.ORCID 0000-0002-6486-3142
Yilin ChenDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Hui ChenDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Na TaDepartment of Pathology, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Xiang NiDepartment of Pathology, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Jingyu ZhangDepartment of Cardiovascular Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Haidong HuangDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Yao FangDepartment of Respiratory and Critical Care Medicine, General Hospital of Central Theater Command of the Chinese People's Liberation Army, Wuhan, China.
Lei QuDepartment of Respiratory and Critical Care Medicine, General Hospital of Central Theater Command of the Chinese People's Liberation Army, Wuhan, China.
Fang YangDepartment of Respiratory and Critical Care Medicine, General Hospital of Central Theater Command of the Chinese People's Liberation Army, Wuhan, China.
Zhenhong HuDepartment of Respiratory and Critical Care Medicine, General Hospital of Central Theater Command of the Chinese People's Liberation Army, Wuhan, China.
Yuchao DongDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
Hui ShiDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China.ORCID 0009-0000-4497-4614
Chong BaiDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai, China.ORCID 0000-0003-2039-5751

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT), as a rare and highly malignant neoplasm associated with a high mortality risk, is easily confused with SMARCA4-deficient nonsmall-cell lung cancer (NSCLC). To date, no standard and effective protocol for thoracic SMARCA4-UT has been established. Immunotherapy has demonstrated efficacy in advanced NSCLC, achieving unprecedented survival benefits. However, immune-related adverse events (irAEs) remain a significant clinical challenge. Here, we reported the first case of thoracic SMARCA4-UT with immune-related cystitis and hypothyroidism, in which the patient benefited from first-line immune checkpoint inhibitor (ICI)-based combination therapy, achieving a remarkable overall survival of over 100 weeks. Furthermore, we performed a review and analysis of the diagnosis, differential diagnosis, immunotherapy, and prognosis of thoracic SMARCA4-UT, proposing that first-line therapy combining immunotherapy with platinum-based chemotherapy (induction and maintenance phases) with or without radiotherapy, may improve the prognosis of such patients. Additionally, we hypothesized a potential role of macrophages in the pathogenesis of immune-related cystitis for the first time and detailed the clinicopathological characteristics and evidence-based management of this irAE.

Indexed as

CystitisDNA HelicasesImmune Checkpoint InhibitorsLung NeoplasmsNuclear ProteinsThoracic NeoplasmsTranscription FactorsAntineoplastic Combined Chemotherapy ProtocolsDiagnosis, DifferentialHumansTreatment OutcomeDNA HelicasesImmune Checkpoint InhibitorsNuclear ProteinsSMARCA4 protein, humanTranscription Factorscase reportimmune checkpoint inhibitorimmune-related cystitisimmunotherapylung cancerthoracic SMARCA4-deficient undifferentiated tumor

Identifiers

PMID41126608
PMCPMC12559638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.